Aardvark Therapeutics, Inc. Common Stock (AARD) — Cash Flow-to-Debt Ratio
Aardvark Therapeutics, Inc. Common Stock (AARD) has a Cash Flow-to-Debt Ratio of -1.71x as of September 2025, meaning its operating cash flow of $-18.52 Million could theoretically repay -2% of its total liabilities ($10.85 Million) in one year. See working capital position of Aardvark Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aardvark Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2022–2024)
Historical debt coverage capacity for Aardvark Therapeutics, Inc. Common Stock across 3 annual periods. Also explore Aardvark Therapeutics, Inc. Common Stock net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aardvark Therapeutics, Inc. Common Stock (2022–2024)
Year-by-year debt coverage analysis for Aardvark Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see market value of Aardvark Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.14x | $-18.09 Million | $132.15 Million | ▼ -6.5% |
| 2023 | -0.13x | $-5.82 Million | $45.34 Million | ▲ +45.6% |
| 2022 | -0.24x | $-10.54 Million | $44.68 Million | — |